^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    NBPF1 (NBPF Member 1)

    i
    Other names: NBPF1, NBPF Member 1, KIAA1693, Neuroblastoma Breakpoint Family Member 1, FLJ20719, Neuroblastoma Breakpoint Family, Member 1, AB13, AB14, AB23, NBPF, AD2, NBG
    Associations

    News

    Trials
    8ms
    Neurodevelopment Genes Encoding Olduvai Domains Link Myalgic Encephalomyelitis to Neuropsychiatric Disorders. (PubMed, Diagnostics (Basel))
    These genes are involved in cortical neurogenesis, brain evolution, and neuroblastoma, and have been implicated by several studies in schizophrenia and autism. The sharing of these associations by the two cohorts supports their validity and grants the necessity of future studies to evaluate the implications for ME/CFS aetiology.
    Journal
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CSMD3 (CUB And Sushi Multiple Domains 3) • NCOA3 (Nuclear Receptor Coactivator 3) • ADGRE5 (Adhesion G Protein-Coupled Receptor E5) • NBPF1 (NBPF Member 1)
    9ms
    DNA methylation in monozygotic twins discordant for acute lymphoblastic leukemia: a case report and systematic review. (PubMed, Clin Epigenetics)
    Furthermore, we systemically reviewed the literatures on leukemia and DNA methylation modifications, providing a comprehensive description of their correlation. In summary, these findings indicate that DNA methylation plays a crucial role in the onset and progression of ALL, offering valuable insights for future research into its impact on leukemia development.
    Review • Journal
    |
    ZDHHC11 (Zinc Finger DHHC-Type Containing 11) • NBPF1 (NBPF Member 1)
    over1year
    5-Fluorouracil resistance-based immune-related gene signature for COAD prognosis. (PubMed, Heliyon)
    In summary, the 5FRRDEG-based prognostic model is an effective tool for targeted therapy and chemotherapy in patients with COAD. It can accurately predict the survival prognosis of these patients as well as to provide the direction for exploring the resistance mechanism underlying COAD.
    Journal • Gene Signature
    |
    SERPINE1 (Serpin Family E Member 1) • NBPF1 (NBPF Member 1)
    |
    5-fluorouracil
    over2years
    Genetic Variations in Multiple Myeloma with Extramedullary Disease (ASH 2023)
    Especially, in WES analysis, CDC27 was mutated only in FFPE of EMM patients, and in Nanostring analysis, IRF4 was up-regulated all EMM samples. Further studies are needed to confirm the genetic alterations in more EMM patients.
    IO biomarker
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCR4 (C-C Motif Chemokine Receptor 4) • S100A8 (S100 Calcium Binding Protein A8) • S100A9 (S100 Calcium Binding Protein A9) • AHNAK2 (AHNAK Nucleoprotein 2) • IRF4 (Interferon regulatory factor 4) • MUC4 (Mucin 4, Cell Surface Associated) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • IL15 (Interleukin 15) • CDKN1C (Cyclin Dependent Kinase Inhibitor 1C) • CEP55 (Centrosomal Protein 55) • MAP2K3 (Mitogen-Activated Protein Kinase Kinase 3) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex) • CDC27 (Cell Division Cycle 27) • NBPF1 (NBPF Member 1)
    over2years
    Integrative Genomic and Transcriptomic Analysis Reveals Genetic Alterations Associated with the Early Progression of Follicular Lymphoma (ASH 2023)
    This result was further validated with transcriptome-wide information provided by RNA-seq at single-cell resolution. Conclusion Our study, performed on a large cohort of FL patients, highlights the importance of distinctive genetic alterations and gene expression relevant to disease diagnosis and early progression.
    IO biomarker • Omic analysis
    |
    BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • B2M (Beta-2-microglobulin) • NBPF1 (NBPF Member 1)
    over2years
    Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma. (PubMed, Br J Haematol)
    This result was further validated with transcriptome-wide information provided by RNA-seq at single-cell resolution. Our study, performed on a large cohort of FL patients, highlights the importance of distinctive genetic alterations and gene expression relevant to disease diagnosis and early progression.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • B2M (Beta-2-microglobulin) • NBPF1 (NBPF Member 1)
    over2years
    Genetic Alterations In Multiple Myeloma With Extramedullary Disease (IMW 2023)
    In our study, significant genetic alterations have been identified. Especially, In particular, in WES analysis, CDC27 was mutated only in FFPE of EMM patients, and in Nanostring analysis, IRF4 was up-regulated all EMM samples. Further studies are needed to confirm the genetic alterations in more EMM patients.
    IO biomarker
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCR4 (C-C Motif Chemokine Receptor 4) • S100A8 (S100 Calcium Binding Protein A8) • S100A9 (S100 Calcium Binding Protein A9) • AHNAK2 (AHNAK Nucleoprotein 2) • IRF4 (Interferon regulatory factor 4) • MUC4 (Mucin 4, Cell Surface Associated) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • IL15 (Interleukin 15) • CDKN1C (Cyclin Dependent Kinase Inhibitor 1C) • CEP55 (Centrosomal Protein 55) • MAP2K3 (Mitogen-Activated Protein Kinase Kinase 3) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex) • CDC27 (Cell Division Cycle 27) • NBPF1 (NBPF Member 1)